1.Does a Gradient-Adjusted Cardiac Power Index Improve Prediction of Post-Transcatheter Aortic Valve Replacement Survival Over Cardiac Power Index?
Pradyumna AGASTHI ; Sai Harika PUJARI ; Farouk MOOKADAM ; Andrew TSENG ; Nithin R. VENEPALLY ; Panwen WANG ; Mohamed ALLAM ; John SWEENEY ; Mackram ELEID ; Floyd David FORTUIN ; David R. HOLMES JR ; Nirat BEOHAR ; Reza ARSANJANI
Yonsei Medical Journal 2020;61(6):482-491
Purpose:
Cardiac power (CP) index is a product of mean arterial pressure (MAP) and cardiac output (CO). In aortic stenosis, however, MAP is not reflective of true left ventricular (LV) afterload. We evaluated the utility of a gradient-adjusted CP (GCP) index in predicting survival after transcatheter aortic valve replacement (TAVR), compared to CP alone.
Materials and Methods:
We included 975 patients who underwent TAVR with 1 year of follow-up. CP was calculated as (CO× MAP)/[451×body surface area (BSA)] (W/m2). GCP was calculated using augmented MAP by adding aortic valve mean gradient (AVMG) to systolic blood pressure (CP1), adding aortic valve maximal instantaneous gradient to systolic blood pressure (CP2), and adding AVMG to MAP (CP3). A multivariate Cox regression analysis was performed adjusting for baseline covariates. Receiver operator curves (ROC) for CP and GCP were calculated to predict survival after TAVR.
Results:
The mortality rate at 1 year was 16%. The mean age and AVMG of the survivors were 81±9 years and 43±4 mm Hg versus 80±9 years and 42±13 mm Hg in the deceased group. The proportions of female patients were similar in both groups (p=0.7). Both CP and GCP were independently associated with survival at 1 year. The area under ROCs for CP, CP1, CP2, and CP3 were 0.67 [95% confidence interval (CI), 0.62–0.72], 0.65 (95% CI, 0.60–0.70), 0.66 (95% CI, 0.61–0.71), and 0.63 (95% CI 0.58–0.68), respectively.
Conclusion
GCP did not improve the accuracy of predicting survival post TAVR at 1 year, compared to CP alone.
2.ABO blood group and rhesus factor association with inpatient COVID-19 mortality and severity: a two-year retrospective review
Alexander T. PHAN ; Ari A. UCAR ; Aldin MALKOC ; Janie HU ; Luke BUXTON ; Alan W. TSENG ; Fanglong DONG ; , Julie P.T. NGUYỄN ; Arnav P. MODI ; Ojas DESHPANDE ; Johnson LAY ; Andrew KU ; Dotun OGUNYEMI ; Sarkis ARABIAN
Blood Research 2023;58(3):138-144
Background:
Early reports have indicated a relationship between ABO and rhesus blood group types and infection with SARS-CoV-2. We aim to examine blood group type associations with COVID-19 mortality and disease severity.
Methods:
This is a retrospective chart review of patients ages 18 years or older admitted to the hospital with COVID-19 between January 2020 and December 2021. The primary outcome was COVID-19 mortality with respect to ABO blood group type. The secondary outcomes were 1. Severity of COVID-19 with respect to ABO blood group type, and 2. Rhesus factor association with COVID-19 mortality and disease severity. Disease severity was defined by degree of supplemental oxygen requirements (ambient air, low-flow, high-flow, non-invasive mechanical ventilation, and invasive mechanical ventilation).
Results:
The blood type was collected on 596 patients with more than half (54%, N=322) being O+. The ABO blood type alone was not statistically associated with mortality (P=0.405), while the RH blood type was statistically associated with mortality (P<0.001). There was statistically significant association between combined ABO and RH blood type and mortality (P=0.014). Out of the mortality group, the O+ group had the highest mortality (52.3%), followed by A+ (22.8%). The combined ABO and RH blood type was statistically significantly associated with degree of supplemental oxygen requirements (P =0.005).The Kaplan-Meier curve demonstrated that Rh- patients had increased mortality.
Conclusion
ABO blood type is not associated with COVID-19 severity and mortality. Rhesus factor status is associated with COVID-19 severity and mortality. Rhesus negative patients were associated with increased mortality risk.
3.The Practice of Gastrointestinal Motility Laboratory During COVID-19 Pandemic: Position Statements of the Asian Neurogastroenterology and Motility Association (ANMA-GML-COVID-19 Position Statements)
Kewin T H SIAH ; M Masudur RAHMAN ; Andrew M L ONG ; Alex Y S SOH ; Yeong Yeh LEE ; Yinglian XIAO ; Sanjeev SACHDEVA ; Kee Wook JUNG ; Yen-Po WANG ; Tadayuki OSHIMA ; Tanisa PATCHARATRAKUL ; Ping-Huei TSENG ; Omesh GOYAL ; Junxiong PANG ; Christopher K C LAI ; Jung Ho PARK ; Sanjiv MAHADEVA ; Yu Kyung CHO ; Justin C Y WU ; Uday C GHOSHAL ; Hiroto MIWA
Journal of Neurogastroenterology and Motility 2020;26(3):299-310
During the Coronavirus Disease 2019 (COVID-19) pandemic, practices of gastrointestinal procedures within the digestive tract require special precautions due to the risk of contraction of severe acute respiratoy syndrome coronavirus-2 (SARS-CoV-2) infection. Many procedures in the gastrointestinal motility laboratory may be considered moderate to high-risk for viral transmission. Healthcare staff working in gastrointestinal motility laboratories are frequently exposed to splashes, air droplets, mucus, or saliva during the procedures. Moreover, some are aerosol-generating and thus have a high risk of viral transmission. There are multiple guidelines on the practices of gastrointestinal endoscopy during this pandemic. However, such guidelines are still lacking and urgently needed for the practice of gastrointestinal motility laboratories. Hence, the Asian Neurogastroenterology and Motility Association had organized a group of gastrointestinal motility experts and infectious disease specialists to produce a position statement paper based-on current available evidence and consensus opinion with aims to provide a clear guidance on the practices of gastrointestinal motility laboratories during the COVID-19 pandemic. This guideline covers a wide range of topics on gastrointestinal motility activities from scheduling a motility test, the precautions at different steps of the procedure to disinfection for the safety and well-being of the patients and the healthcare workers. These practices may vary in different countries depending on the stages of the pandemic, local or institutional policy, and the availability of healthcare resources. This guideline is useful when the transmission rate of SARS-CoV-2 is high. It may change rapidly depending on the situation of the epidemic and when new evidence becomes available.